



Announcement Summary

---

**Entity name**

CRESO PHARMA LIMITED

**Announcement Type**

New announcement

**Date of this announcement**

10/10/2022

**The Proposed issue is:**

A placement or other type of issue

**Total number of +securities proposed to be issued for a placement or other type of issue**

ASX +security code	+Security description	Maximum Number of +securities to be issued
New class-code to be confirmed	Options	2,000,000

**Proposed +issue date**

30/11/2022

Refer to next page for full details of the announcement



## Part 1 - Entity and announcement details

---

### 1.1 Name of +Entity

CRESO PHARMA LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

### 1.2 Registered Number Type

ABN

### Registration Number

89609406911

### 1.3 ASX issuer code

CPH

### 1.4 The announcement is

New announcement

### 1.5 Date of this announcement

10/10/2022

### 1.6 The Proposed issue is:

A placement or other type of issue



## Part 7 - Details of proposed placement or other issue

## Part 7A - Conditions

**7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?** Yes

## 7A.1a Conditions

Approval/Condition	Date for determination	Is the date estimated or actual?	** Approval received/condition met?
+Security holder approval	30/11/2022	<input checked="" type="checkbox"/> Estimated	No

**Comments**

Subject to shareholder approval, the Company has agreed to issue 2,000,000 options to director, Ben Quirin as an equity based incentive component to his remuneration package.

## Part 7B - Issue details

**Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?**

 New class

**Will the proposed issue of this +security include an offer of attaching +securities?**

 No

Details of +securities proposed to be issued

**ISIN Code (if Issuer is a foreign company and +securities are non CDIs)**

**Have you received confirmation from ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1?**

 No

**Will the entity be seeking quotation of the 'new' class of +securities on ASX?**

 No**ASX +security code**

New class-code to be confirmed

**+Security description**

Options



### +Security type

Options

### Number of +securities proposed to be issued

2,000,000

### Offer price details

#### Are the +securities proposed to be issued being issued for a cash consideration?

No

#### Please describe the consideration being provided for the +securities

Subject to shareholder approval, the Company has agreed to issue 2,000,000 options to Ben Quirin, as an equity based incentive component to his director remuneration package. The Options will vest and become exercisable as follows:

- 1/3 of the options will vest on the date that is six months after Mr Quirin's date of appointment as a director of the Company;
- 1/3 of the options will vest on the date that is twelve months after Mr Quirin's date of appointment as a director of the Company; and
- 1/3 of the options will vest on the date that is eighteen months after Mr Quirin's date of appointment as a director of the Company.

#### Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities

#### Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

### Options details

+Security currency	Exercise price	Expiry date
AUD - Australian Dollar	AUD 0.0400	10/10/2024

#### Details of the type of +security that will be issued if the option is exercised

CPH : ORDINARY FULLY PAID

#### Number of securities that will be issued if the option is exercised

One fully paid share (ASX:CPH).

#### Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.

Refer to the ASX release announcing the appointment of Mr Quirin to the Company. Please note that the material terms of these options will be included in a future Notice of Meeting for a General Meeting, to be released on the ASX in due course.



Part 7C - Timetable

---

**7C.1 Proposed +issue date**

30/11/2022

Part 7D - Listing Rule requirements

---

**7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?**

No

**7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

No

**7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?**

No

**7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?**

Yes

**7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?**

No

**7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?**

No

Part 7E - Fees and expenses

---

**7E.1 Will there be a lead manager or broker to the proposed issue?**

No

**7E.2 Is the proposed issue to be underwritten?**

No

**7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue**

N/A



Part 7F - Further Information

---

**7F.01 The purpose(s) for which the entity is issuing the securities**

Proposed issue of options to director, Mr Ben Quirin, as an equity based incentive to his director remuneration.

**7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?**

No

**7F.2 Any other information the entity wishes to provide about the proposed issue**

The proposed date of the general meeting and date of issue of the options included in this Appendix 3B are estimates only.